Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05115955
Other study ID # B202105153
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date November 11, 2021
Est. completion date October 14, 2024

Study information

Verified date November 2023
Source Tri-Service General Hospital
Contact Chueng-He Lu, M.D.
Phone +886-2-87927128
Email box1971boy@yahoo.com.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Postoperative pain is common, and the pain intensity can be moderate to severe depending on the site of surgery during the first few days after surgery, and an estimated 15% to 45% experience chronic postsurgical pain. When poorly controlled, the pain can have a significant effect on patient recovery. Proper management of postoperative pain is needed to relieve suffering and lead to earlier mobilization, shortened hospital stay, reduced hospital costs, and increased patient satisfaction. The currently proposed clinical use of Dinalbuphine Sebacate is to administer a single dose of NALDEBAIN® intramuscularly approximately 12 to 24 hours prior to the planned surgery for pain relief. Several clinical studies of NALDEBAIN® have been published, such as the use in laparotomy and laparoscopic cholecystectomy. However, toward the arthroscopic shoulder surgery, no article or report has been available publicly yet. The primary objective of this study is to determine the safety and efficacy of single doses of intramuscular NALDEBAIN® on patients scheduled to undergo arthroscopic shoulder surgery.


Description:

This is a randomized, double-blind, placebo controlled study. Patients scheduled to undergo arthroscopic shoulder surgery will be invited to participate in this study. After obtaining the written informed consent, each subject should be sequentially assigned an individual screening number instead of his/her name, chart number or identification. Subjects will be randomized to two groups, DS group and Control group. Both groups should be treated with both routine analgesic regimen and a dose of investigational product. Random numbers and assignment treatment were generated by computer program before this study initiated. Statistical analyses should be performed on the data to compare the two groups. Numerical variables will be present with mean and standard deviation and categorical variables will be present with number and percentage.


Recruitment information / eligibility

Status Recruiting
Enrollment 76
Est. completion date October 14, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria: 1. Scheduled to undergo arthroscopic shoulder surgery. 2. American Society of Anesthesiology Physical Class 1-3. 3. Ability and willingness to provide informed consent. Exclusion Criteria: 1. Not willing to adhere to the study visit schedule. 2. With a history of hypersensitivity or allergy to opioids, NSAIDs or sesame oil. 3. With a medical history that may predispose them to abnormal intracranial pressure. 4. Any history of narcotic dependency, addiction, or withdrawal. 5. Any clinically significant condition that may interfere with study assessments. 6. Pregnant or breastfeeding. 7. Nonregular sinus cardiac rhythm or implanted pacemakers. 8. Prescribed antimuscarinic agents, a2-adrenergic agonists, ß1-adrenergic antagonists, or antiarrhythmic agents.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DS group
In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.
Control group
In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.

Locations

Country Name City State
Taiwan Tri-Service General Hospital Taipei city

Sponsors (1)

Lead Sponsor Collaborator
Tri-Service General Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute postoperative pain intensity Mean pain intensity scored by numeric rating scale (NRS). Numerical Rating Scale (NRS) was a 11-point scale on which 0 represented "no pain" and 10 represented the" worst pain ever". Within 1 day after surgery
Primary Brief Pain Inventory Mean scores of each item in Brief Pain Inventory (BPI). Patients fill out 11 different NRS that ask about pain intensity and the effect of the pain on their ability to function during various activities of daily living. The severity scores range from 0 (no pain) to 10 (the most severe pain). Within 1 day after surgery
Secondary Postoperative pain intensity Mean pain intensity scored by numeric rating scale (NRS). Numerical Rating Scale (NRS) was a 11-point scale on which 0 represented "no pain" and 10 represented the" worst pain ever". In postanesthesia care unit (PACU), and 6 hours, 7 days, 90 days, and 180 days after surgery
Secondary Consumption of analgesics The consumption of total amount (mg) of supplemental analgesics administered after surgery. Within 7 days after surgery
Secondary Time to the first dose of rescue medication Time from the end of surgery to the first rescue medication use. Up to 7 days after surgery
Secondary Brief Pain Inventory Mean scores of each item in Brief Pain Inventory (BPI). Patients fill out 11 different NRS that ask about pain intensity and the effect of the pain on their ability to function during various activities of daily living. The severity scores range from 0 (no pain) to 10 (the most severe pain). At baseline, 1 day, 7 days, 90 days, 180 days after surgery
Secondary Satisfaction assessed by a 5-point scale Each subject should be asked the following question: "How satisfied were you with your post-surgical analgesia"? Subjects should be asked to classify themselves as either: 1=highly satisfied, 2=satisfied, 3=uncertain, 4=dissatisfied or 5=very dissatisfied. 7 days after surgery
Secondary Incidence of adverse events The incidence of postoperative adverse events occurring during 7 days after surgery, especially the ones related to analgesics. Within 7 days after surgery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04905355 - Virtual Reality on Patient Satisfaction in Ambulatory Orthopedic Surgery N/A
Active, not recruiting NCT01123447 - Surgical Treatment Versus Non-surgical Treatment of Ulnar Fractures N/A
Completed NCT00835653 - Efficacy of Median Nerve Block Performed Using Echographic Guidance N/A
Withdrawn NCT01221415 - A Comparison of Ultrasound and Nerve Stimulator Techniques for Nerve Localization in Regional Anesthesia
Recruiting NCT05437796 - Immersive Virtual Reality in Orthopedics N/A
Not yet recruiting NCT03327337 - Arthroscopic Assisted Balloon Tibioplasty for the Treatment of Schatzker II-IV Tibial Plateau Fractures N/A
Enrolling by invitation NCT04398342 - Characteristics of Children With Cerebral Palsy Who Develops Hip Displacement in Denmark
Not yet recruiting NCT04657952 - Sphenopalatine Ganglion Block for Post-Dural Puncture Headache in Orthopedic Patients Phase 4
Recruiting NCT03701269 - Long-term Surgical Outcomes of Scaphoid Proximal Pole Fracture Nonunion
Active, not recruiting NCT03113734 - Clinical Screening of Acute Ruptures of the Anterior Cruciate Ligament of the Knee
Recruiting NCT04792359 - Intra and Inter- Observer Reproducibility of Ankle Dorsiflexion Measure With a New Tool N/A